Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_212_библиотеки_им_акад_М_И_Перельмана
.pdf
191
Вопросы практической педиатрии. – 2019. – № 14(5). – С. 108–115. – Doi:
10.20953/1817–7646–2019–5–108–115
37. Системы молекулярно–генетических маркеров при раке желудка / М.В.
Немцова, И.И. Быков, Н.В. Чекунова [и др.] // Клиническая лабораторная
диагностика. – 2013. – № 11. – С. 12–15.
38. Скоропад, В. Ю. Рациональная тактика лечения местно–
распространенного рака желудка: место лучевой терапии / В.Ю. Скоропад //
Практическая онкология. – 2009 – № 1. – C. 28.
39. Состояние онкологической помощи населению России в 2021 году / Под
ред. А. Д. Каприна, В. В. Старинского, А. О. Шахзадовой. – Москва: МНИОИ им.
П.А. Герцена, 2022. – 239 c. – ISBN 978–5–85502–275–9. – Текст:
непосредственный.
40. TNM: Классификация злокачественных опухолей / Под ред. Дж.Д.
Брайерли и др.; пер. с англ. и научн. ред. Е.А. Дубовой, К.А. Павлова. 2-е изд. на
русском языке. - М.: Логосфера, 2018. - 344 с. – ISBN 978-5-98657-063-1.
41. Урбах, В. Ю. Математическая статистика для биологов и медиков / В.Ю.
Урбах. – М.: Изд–во АН СССР, 1963. – 322 с.
42. Характеристика апоптоза, некроза и особенностей клеточного цикла в
опухолевой ткани при уротелиальной карциноме / Е.В. Слепов, Э.В. Семенов, А.В.
Мазаев [и др.] // Сибирское медицинское обозрение. – 2016. – № 6 (102). – С. 17—
24.
43. Хирургическое лечение местно–распространенного рака желудка / А.Ф.
Черноусов, Т.В. Хоробрых, Д.В. Вычужанин, М.М. Рогаль // Вестник
хирургической гастроэнтерологии. – 2010. – №1. – С. 4.
44. Цитотоксин – ассоциированный ген А (CAGA) Helicobacter pylori:
парадигма онкогенного фактора вирулентности / А.И. Юнусова, И.С. Литвинова,
П.А. Kарпенок, А. Тохидпур // Journal of Siberian federal university. Biology. – 2018.
– №1. – С. 4–15.
45. Чекунова, Н. В. Молекулярно-генетическая диагностика изменений
слизистой культи желудка у больных, оперированных по поводу рака: дис. ... канд.
https://t.me/med1917
192
мед. наук: 14.01.17 / Чекунова Наталия Валерьевна. – Первый МГМУ имени И.М.
Сеченова Минздрава России (Сеченовский университет). – Москва, 2014.– 139
с.
46. Чориев, Э. Б. Молекулярно-биологические и молекулярно-генетические
маркерыв диагностике и лечении рака желудка / Э. Б. Чориев, М. А. Гафур-Ахунов
// Клиническая и экспериментальная онкология. – 2020. – № 3. – С. 78–85.
47. Шайхаев, Е. Г. Молекулярно-генетические характеристики рака желудка
/ Е.Г. Шайхаев, Б.Л. Лыгданова. // Вестник Российского научного центра
рентгенорадиологии. – 2017. – Т.17. – № 3. – С. 3. – URL:
https://vestnik.rncrr.ru/vestnik/v17/docs/shahlyaev.pdf (дата обращения: 10.02.2023).
48. Шушвал, М. С. Морфологическая характеристика фоновых и
предопухолевых процессов при карциномах желудка : дис. ... канд. мед. наук : 3.3.2.
/ Шушвал Михаил Сергеевич. – ФГБНУ «Российский научный центр хирургии
имени академика Б.В. Петровского. – Калининград, 2022. – 154 с.
49. A familial gastrointestinal cancer clinic: organization, aims and activities,
2004–2007 / P. Rozen, Z. Levi, R. Hazazi, [et al.] // Isr Med Assoc J. – 2008. – Vol.
10(10). – P. 695–8. – PMID: 19009948.
50. ASA Physical Status Classification System. Accessed May 25, 2021. – URL:
https://www.asahq.org/standards–and–guidelines/asa–physical–status–classification–
system (Accessed: 14.11.2023).
51. Bae, J. M. Epstein–Barr virus and gastriccancer risk: a meta–analysis with
meta–regression of case-controlstudies / J.M. Bae, E.H. Kim // Journal of Preventive
Medicine and Public Health. – 2016. – Vol. 49(2). – P. 97–107. –
https://doi.org/10.3961/jpmph.15.068.
52. Becker, P. S. Hematopoietic growth factors. NCCN Clinical Practice
Guidelines in Oncology (NCCN Guidelines). Version 2 / P.S. Becker – 2020. – P. 98.
53. Benedict, M.A. Gastric Adenocarcinoma of the Fundic Gland Type: Update
and Literature Review / M.A. Benedict, G.Y. Lauwers, D. Jain // Am J Clin Pathol. –
2018. – Vol. 149(6). – P. 461–473. –https://doi.org/10.1093/ajcp/aqy019.
https://t.me/med1917
193
54. Bertoli, G. MicroRNAs: New Biomarkers for Diagnosis, Prognosis, Therapy
Prediction and Therapeutic Tools for Breast Cancer / G. Bertoli // Theranostics. – 2015.
– Vol. 5(10). – P. 1122–43.
55. Blow, N. Tissue preparation: tissue issues / N. Blow // Nature. – 2007. – Vol.
448. – P. 959–63.
56. Bosman, F.T. WHO Classification of Tumours of the Digestive System / F.T.
Bosman. – Lyon, 2010. – P. 48–58.
57. Boussioutas, A. Distinctive patterns of gene expression in premalignant gastric
mucosa and gastric cancer / A., Boussioutas, H. Li, J. Liu J. // Cancer Res. – 2003. – Vol.
63. – P. 2569–2577.
58. Bray, F. Global cancer statistics. GLOBOCAN estimates of incidence and
mortality worldwide for 36 cancers in 185 countries / F. Bray, J. Ferlay, I. Soerjomataram
// CA Cancer J Clin. – 2018. – Vol. 68. – P. 394–424.
59. Bumgarner, R. DNA microarrays: Types, / R. Bumgarner // Curr Protoc Mol
Biol. – 2013.
60. Cancer Genome Atlas Research N. Comprehensive molecular characterization
of gastric adenocarcinoma // Nature. – 2014. – Vol. 513. – P. 202–209. –
https://doi.org/10.1038/nature13480.
61. Cao, W. Role of miR–647 in human gastric cancer suppression / W. Cao //
Oncol. Rep. – 2017. – Vol. 37 (3). – P. 1401–1411.
62. Castro, A. Elevated neoantigen levels in tumors with somatic mutations in the
HLA–A, HLA–B, HLA–C and B2M genes / A. Castro, K. Ozturk, R.M. Pyke // BMC
Med Genomics. – 2019. – 12(6). – P. 107. – doi: 10.1186/s12920–019–0544–1. PMID:
31345234; PMCID: PMC6657029.
63. CD44v6, MMP–7 and nuclear Cdx2 are significant biomarkers for prediction
of lymph node metastasis in primary gastric cancer / H. Okayama, K. Kumamoto, K.
Saitou, [et al.] // Oncology Reports. – 2009. – Vol. 22(4). – P. 24–31.
64. CD47 expression in Epstein–Barr virus–associated gastric carcinoma:
coexistence with tumor immunity lowering the ratio of CD8(+)/Foxp3(+) T cells / H. Abe,
https://t.me/med1917
194
R. Saito, T. Ichimura [et al.] // Virchows Arch. – 2018. – Vol. 472(4). – P. 643–651. –
https://doi.org/10.1007/s00428–018–2332–2.
65. Changing trends in stomach cancer throughout the world / M. Balakrishnan, R.
George, A. Sharma, D.Y. Graham // Curr Gastroenterol Rep. – 2017. – Vol. 19. – P. 36.
66. Cho, J. Y. Gene expression signature–based prognostic risk score in gastric
cancer / J.Y. Cho, J.Y. Lim, J.H. Cheong // Clin Cancer Res. – 2011. – Vol. 17. – P. 1850–
1857.
67. Circulating levels of GDF15, MMP7 and miR–200c as a poor prognostic
signature in gastric cancer / M. Blanco–Calvo M, N. Tarrío N, M. Reboredo [et al.] //
Future Oncol. – 2014. – Vol. 10(7). – P. 1187–202.
68. Clavien, P. A. Proposed classification of complications of surgery with
examples of utility in cholecystectomy / P. A. Clavien, J. R. Sanabria, S. M. Strasberg //
Surgery. – 1992. – Vol. 111. – P. 518–526.
69. Clinicopathological Variation of Lauren Classification in Gastric Cancer / Y.C.
Chen, W.L. Fang, R.F. Wang [et al.] // Pathol Oncol Res. – 2016. – Vol. 22 (1). – P. 197–
202.
70. Correlation between GDF15, MMP7 and gastric cancer and its prognosis / Lu
L, G.Q. Ma, X.D. Liu, [et al.] // Eur Rev Med Pharmacol Sci. – 2017. – 21 (3). – P. 535–
541. – PMID: 28239815.
71. Crew, K. D. Epidemiology of gastric cancer / K.D. Crew // World J.
Gastroenterol. – 2006. – Vol. 12, № 3. – P. 354–362.
72. Cristescu, R. Molecular analysis of gastric cancer identifies discrete subtypes
associated with distinct clinical characteristics and survival outcomes: the ACRG (Asian
Cancer Research Group) study / R. Cristescu, J. Lee, M. Nebozhyn // Nat Med. – 2015. –
Vol. 21. – P. 449–456. – https://doi.org/10.1038/nm.3850.
73. Cui, N. Biochemical and Biological Attributes of Matrix Metalloproteinases /
N. Cui, M. Hu, R.A. Khalil // Progress in Molecular Biology and Translational Science.
– 2017. – Vol. 147. – P. 1–73.
https://t.me/med1917
195
74. Cui, P. Current status and progress in the standardized surgical management of
specimens after radical gastric cancer surgery / P. Cui // Zhonghua Wei Chang Wai Ke
Za Zhi. – 2022. – Vol. 25. – №. 2. – P. 179–183.
75. De Boer, M. T. Impact of blood loss on outcome after liver resection / M. T.
De Boer, I. Q. Molenaar, R. J. Porte // Dig. Surg. – 2007. – Vol. 24, № 4. – P. 259–264.
76. Deng, N. A comprehensive survey of genomic alterations in gastric cancer
reveals systematic patterns of molecular exclusivity and co–occurrence among distinct
therapeutic targets / N. Deng, L.K. Goh, H. Wang // Gut. – 2012. – Vol. 61. – P. 673–84.
77. Dindo, D. Classification of surgical complications: A new proposal with
evaluation in a cohort of 6336 patients and results of a survey / D. Dindo, N. Demartines,
P.A. Clavien // Ann. Surg. – 2004. – Vol. 240, № 2. – P. 205.
78. Distribution of p53 mutations in esophageal and gastric carcinomas and the
relationship with p53expression / K. Hanazono, S. Natsugoe, H.J. Stein, [et al]. // Oncol
Rep. – 2006. – Vol. 15. – P. 821–824.
79. Dulak, A.M. Gastrointestinal adenocarcinomas of the esophagus, stomach, and
colon exhibit distinct patterns of genome instability and oncogenesis / A.M. Dulak, S.E.
Schumacher // Cancer Res. – 2012. – Vol. 72. – P. 4383–4393.
80. Edwards, P.A. Fusion genes and chromosome translocations in the common
epithelial cancers / P.A. Edwards // J Pathol. – 2010. – Vol. 220. – P. 244–254.
81. Endoscopic surveillance with systematic random biopsy for the early diagnosis
of hereditary diffuse gastric cancer: a prospective 16–year longitudinal cohort study /
C.Y.C. Lee, A. Olivier, J. Honing, A.M. Lydon, S. Richardson, M. O'Donovan, M.
Tischkowitz, R.C. Fitzgerald, M. di Pietro // Lancet Oncol. – 2023. – Vol. 24(1). – P.
107–116. – doi: 10.1016/S1470–2045(22)00700–8.
82. Exome sequencing of gastric adenocarcinoma identifies recurrent somatic
mutations in cell adhesion and chromatin remodeling genes / Z.J. Zang, I. Cutcutache,
S.L. Poon, [et al.] // Nat Genet. – 2012. – Vol. 44. – P. 570–574.
83. Eyvazi, S. CpG Islands Methylation Analysis of CDH11, EphA5, and HS3ST2
Genes in Gastric Adenocarcinoma Patients / S. Eyvazi // J Gastrointest Cancer. – 2020. –
Vol. 51(2). – P. 579–583.
https://t.me/med1917
196
84. Frequent microsatellite instability in papillary and solid type, poorly
differentiated adenocarcinomas of the stomach / T. Arai, U. Sakurai, M. Sawabe [et al.]
// Gastric Cancer. – 2013. – Vol. 16(4). – P. 505–512. –https://doi.org/10.1007/s10120–
012–0226–6.
85. Frequent promoter methylation of CDH1 in non–neoplastic mucosa of sporadic
diffuse gastric cancer / K.H. Lee, D. Hwang, K.Y. Kang, [et al.] // Anticancer Res. – 2013.
– Vol. 33. – P. 3765–3774.
86. Fu, C. K. The Association of MMP7 Promoter Polymorphisms with Gastric
Cancer / C.K. Fu // Anticancer Res. – 2020. – Vol. 40(2). – P. 695–702.
87. Fu, D. G. Epigenetic alterations in gastric cancer (Review) / D.G. Fu // Mol
Med Rep. – 2015. – Vol. 12. – P. 3223–3230.
88. Gaetano, S. Editor microRNA. Basic Science from Molecular Biology to
Clinical Practice / S. Gaetano. – 2015. – 267 p.
89. Ganesan, K. Inhibition of gastric cancer invasion and metastasis by PLA2G2A,
a novel beta–catenin/ TCF target gene / K. Ganesan, T. Ivanova, Y. Wu // Cancer Res. –
2008. – Vol. 68. – P. 4277–4286.
90. Gao, J. J. Luminal A Breast Cancer and Molecular Assays: A Review / J.J. Gao
// Oncologist. – 2018. – Vol. 23(5). – P. 556–565.
91. Gastric parietal cell carcinoma–a newly recognized entity: light microscopic
and ultrastructural features / C. Capella, B. Frigerio, M. Cornaggia M. [et al.] //
Histopathology. – 1984. – Vol. 8(5). – P. 813–824. –https://doi.org/10.1111/j.1365–
2559.1984.tb02397.x.
92. Giacomini, C. P. Breakpoint analysis of transcriptional and genomic profiles
uncovers novel gene fusions spanning multiple human cancer types / C.P. Giacomini, S.
Sun, S. Varma // PLoS Genet. – 2013. – Vol. 9. – P. 42–48.
93. Global Cancer Observatory: Can–cer Today / J. Ferlay, M. Ervik, F. Lam //
Lyon, France: International Agency for Research on Cancer. – 2018. – URL:
https://gco.iarc.fr/today (Accessed: 14.11.2023).
94. Ha, M., Regulation of microRNA biogenesis / M. Ha, V.N. Kim // Nat Rev Mol
Cell Biol. – 2014. – Vol. 15. – P. 509–524.
https://t.me/med1917
197
95. Haveri, H. Transcription factors GATA–4 and GATA–6 in normal and
neoplastic human gastrointestinal mucosa / H. Haveri, M. Westerholm–Ormio, K.
Lindfors // BMC Gastroenterol. – 2008. – Vol. 8. – P. 9.
96. Hayashi, I. Mucoepidermoid carcinoma of the stomach / I. Hayashi // J Surg
Oncol. – 1987. – Vol. 34(2). – P. 94–99. – URL: https://doi.org/10.1002/jso.2930340206
(Accessed: 14.11.2023).
97. HER2 expression in gastric cancer: Rare, heterogeneous and of no prognostic
value – conclusions from 924 cases of two independent series / H. Grabsch, S. Sivakumar,
S. Gray [et al.] // Cell Oncol. – 2010. – Vol. 32(1–2). – P. 57–65. – doi.org/10.3233/clo–
2009–0497.
98. Hereditary Diffuse Gastric Cancer Syndrome: CDH1 Mutations and Beyond /
S. Hansford, P. Kaurah, H. Li–Chang H., [et al.] // JAMA Oncol. – 2015. – Vol. 1. – P.
23–32.
99. High–throughput protein and mRNA expression–based classification of gastric
cancers can identify clinically distinct subtypes, concordant with recent molecular
classifications / S. Ahn, S. J. Lee, Y. Kim [et al.] // Am J Surg Pathol. – 2017. – Vol.
41(1). – P. 106–115. –https://doi.org/10.1097/pas.0000000000000756.
100. Hissong, E. Gastric Carcinomas with Lymphoid Stroma: An Evaluation of
the Histopathologic and Molecular Features Am / E. Hissong // J Surg Pathol. – 2018. –
Vol. 42(4). – P. 453–462. – URL: https://doi.org/10.1097/pas.0000000000001018
(Accessed: 14.11.2023).
101. Helicobacter pylori in human health and disease: mechanisms for local
gastric and systemic effects / D. Bravo, A. Hoare, C. Soto, M.A. Valenzuela // World J
Gastroenterol. – 2018. – Vol. 24(28). – P. 3071–3089.
102. Helicobacter pylori and gastric cancer: adaptive cellular mechanisms
involved in disease progression / P. Díaz, Valderrama M. Valenzuela, J. Bravo, AFG.
Quest // Front Microbiol. – 2018. – Vol. 9. – P. 5.
103. Huang, T. MicroRNAs serve as a bridge between oxidative stress and gastric
cancer (Review) / T. Huang // International Journal of Oncology. – Vol. 49. – P. 1791–
1800. – URL: https://doi.org/10.3892/ijo.2016.3686 (Accessed: 14.11.2023).
https://t.me/med1917
198
104. Early gastric cancer in young, asymptomatic carriers of germline E–cadherin
mutations / D.G. Huntsman, F. Carneirom F.R. Lewis, [et al.] // NEJM. – 2001. – Vol.
344 (25). – P. 1904–1909. – doi: 10.1056/NEJM200106213442504.
105. Ii, M. Role of matrix metalloproteinase–7 (matrilysin) in human cancer
invasion, apoptosis, growth, and angiogenesis / M. Ii. // Experimental Biology and
Medicine. – 2006. – Vol. 231(1). – P. 20–27.
106. Induction of microRNA–155 during Helicobacter pylori infection and its
negative regulatory role in the inflammatory response / X. Bin, L. Zhen, L. Bo–Sheng,
[et al.] // J. Infect. – 2009. – Vol. 200 (6). – P. 916–925.
107. Integrative network analysis reveals active microRNAs and their functions
in gastric cancer / C.W. Tseng, C.C. Lin, C.N. Chen, [et al.] // BMC Syst. Biol. – 2011. –
BMC Syst Biol. – Vol. 26. – P. 5–12.
108. Isaacson, K. J. Matrix–metalloproteinases as targets for controlled delivery
in cancer: An analysis of upregulation and expression / K. J. Isaacson // Journal of
Controlled Release. – 2017. – Vol. 259. – P. 62–75.
109. Japanese Classification of Gastric Carcinoma – 2nd English Edition //
Gastric Cancer. – 1998. – Vol. 1(1). – P. 10–24.
110. Japanese Gastric Cancer Association. Japanese gastric cancer treatment
guidelines 2018 (5th edition). – Gastric Cancer 24. – 1–21 (2021). –
https://doi.org/10.1007/s10120–020–01042–y.
111. Kakiuchi, M. Recurrent gain-of-function mutations of RHOA in diffuse–
type gastric carcinoma / M. Kakiuchi // Nat Genet. – 2014. – Vol. 46. – P. 583–587.
112. Kawazoe, A. Clinicopathological features of programmed death ligand 1
expression with tumor–infiltrating lymphocyte, mismatch repair, and Epstein–Barr virus
status in a large cohort of gastric cancer patients / A. Kawazoe // Gastric Cancer. – 2017.
– Vol. 20(3). – P. 407–415. – URL: https://doi.org/10.1007/s10120–016–0631–3
(Accessed: 14.11.2023).
113. Kim, K. C. Suppression of metastasis through inhibition of chitinase 3–like
1 expression by miR–125a–3p–mediated up–regulation of USF1 / K.C. Kim //
Theranostics. – 2018. – Vol. 8 (16). – P. 4409–4428.
https://t.me/med1917
199
114. Kitoh, T. Increased expression of matrix metalloproteinase–7 in invasive
early gastric cancer / T. Kitoh, H. Yanai, Y. Saitoh // J Gastroenterol. – 2004. – Vol. 39
(5). – P. 434–40. – doi: 10.1007/s00535–003–1316–3.
115. Lack of microRNA–101 causes E–cadherin functional deregulation through
EZH2 up–regulation in intestinal gastric cancer / J. Carvalho, N.C. van Grieken, P.M.
Pereira [et al.] // J Pathol. – 2012. – Vol. 228. – P. 31–44.
116. Lan, F. Epigenetic regulation: methylation of histone and non–histone
proteins / F. Lan, Y. Shi // Sci China C Life Sci. – 2009. – Vol. 52. – P. 311–322.
117. Lauren P. The two histological main types of gastric carcinoma: Diffuse and
so–called intestinal–type carcinoma. An attempt at a histoclinical classification / P.
Lauren // Acta Pathol Microbiol Scand. – 1965. – Vol. 64. – P. 31–49.
118. Lee, J. Identification of ROS1 rearrangement in gastric adenocarcinoma / J.
Lee // Cancer. – 2013. – Vol. 119. – P. 1627–1635.
119. Lee, J.W.J. Severity of gastric intestinal metaplasia predicts the risk of
gastric cancer: a prospective multicentre cohort study (GCEP) / J.W.J. Lee // Gut. – 2022.
– Vol. 71(5). – P. 854–863.
120. Li, Z. Comparison of CDH1 Gene Hypermethylation Status in Blood and
Serum among Gastric Cancer Patients / Z. Li, Z. Guo // Pathol Oncol Res. – 2020. – Vol.
26 (2). – P. 1057–1062. – doi: 10.1007/s12253–019–00658–5.
121. Li, B. S. Plasma microRNAs, miR–223, miR–21 and miR–218, as novel
potential biomarkers for gastric cancer detection / B.S. Li // PLoS One. – 2012. – Vol. 7.
– P. 14–21.
122. Li, B. T. MicroRNA–144–3p suppresses gastric cancer progression by
inhibiting epithelial–to–mesenchymal transition through targeting PBX3, Biochem.
Biophys / B.T. Li // Res. Commun. – 2017. – Vol. 484 (2). – P. 241–247.
123. Li, E. DNA methylation in mammals / E. Li, A. Bird // Cold Spring Harbor
Laboratory Press. – 2007. – V.6(5) – P. 341–356.
124. Li, Y. Predictive value of CHFR and MLH1 methylation in human gastric
cancer / Y. Li // Gastric Cancer. – 2015. – V. 18(2) – P. 280–287.
https://t.me/med1917
200
125. Liu X. E-cadherin and gastric cancer: cause, consequence, and Liu, X. E–
cadherin and gastric cancer: cause, consequence, and applications / X. Liu, K.M. Chu //
Biomed Res Int. – 2014. – V. 8 – P. 21–27.
126. Lu, P. The extracellular matrix: A dynamic niche in cancer progression / P.
Lu // Journal of Cell Biology. – 2012. – Vol. 196(4). – P. 395–406.
127. Ludwig, H. Iron metabolism and iron supplementation in cancer patients /
H. Ludwig // Wien. Klin. Wochenschr. Springer–Verlag Wien. – 2015. – Vol. 127, №
23–24. – P. 907–919.
128. Machado, J.C. E–cadherin gene mutations provide a genetic basis for the
phenotypic divergence of mixed gastric carcinomas / J.C. Machado // Lab Invest. – 1999.
– Vol. 79(4). – P. 459–465.
129. Machin, M. Systematic review on the benefit of graduated compression
stockings in the prevention of venous thromboembolism in low-risk surgical patients / M.
Machin // Phlebology. – 2021. – V. – 36(3). – 184–193.
130. Marrelli, D. Multimodal treatment of gastric cancer in the west: Where are
we going? / D. Marrelli // World J Gastroenterol. – 2015. – Vol. 21(26). – P. 7954–7969.
– URL: https://doi.org/10.3748/wjg.v21.i26.7954 (Accessed: 14.11.2023).
131. Masaaki, N. MicroRNA signatures in Helicobacter pyloriinfected gastric
mucosa / N. Masaaki // Int. J. Cancer. – 2015. – Vol. 128 (2). – P. 361–370.
132. Matos, J. I. H. pylori CagA and VacA genotypes and gastric phenotype: a
meta–analysis / J. I. Matos // European Journal of Gastroenterology & Hepatology. –
2013. – Vol. 25. – № 12. – Р. 1431–1441.
133. McAnena, P. Role of micro–RNAs in breast cancer surgery / P. McAnena //
Br J Surg. – 2018. – Vol. 105(2). – P. 36–45.
134. Methylation and Polymorphism in CDH1 Gene Promoter Among Patients
with Diffuse Gastric Cancer / M.N. Vishteh, M. Zeinalian, M. Kheirollahi, [et al.] // Int J
Prev Med. – 2022(13). – P. 44. doi: – 10.4103/ijpvm.IJPVM_288_20.
135. Microsatellite instability in Gastric Cancer: Between lights and shadows / E.
Puliga, S. Corso, F. Pietrantonio, S. Giordano // Cancer Treat Rev. – 2021. – Vol. 95. –
P. 102–175. – doi: 10.1016/j.ctrv.2021.102175.
https://t.me/med1917
Соседние файлы в папке Библиотека им академика М.И. Перельмана